Investment Rating - The report maintains an investment rating of "Buy" with a target price of HKD 16.26 [1][10]. Core Insights - The company reported a revenue of USD 960 million for 2025, representing a year-on-year increase of 61.4%, primarily due to the recognition of licensing revenue from Legend Biotech. However, it incurred a net loss of USD 532 million, which is an increase in loss compared to the previous year, mainly due to losses from Legend Biotech and impairment charges [6][9]. - The adjusted net profit from continuing operations was USD 230 million, reflecting a significant year-on-year increase of 285% [6]. - The report expresses optimism regarding the orderly growth and recovery of profitability across various business segments, maintaining a "Buy" rating based on industry trends and scale effects [6]. Financial Performance Summary - **Revenue Growth**: The life sciences segment generated USD 522 million (+14.8% YoY), while the CDMO segment saw a remarkable increase of USD 389 million (+309.1% YoY) due to licensing revenue [7]. - **Profitability**: The adjusted operating profit for the life sciences segment was USD 95 million with a profit margin of 18%, and the CDMO segment turned profitable with an adjusted operating profit of USD 194 million [7]. - **Future Projections**: For 2026, the company expects revenue growth of 15-18% in the life sciences segment and a 20-25% increase in FFS revenue for CDMO [8]. Business Segment Analysis - **Life Sciences**: Expected revenue growth of 15-18% in 2026, with an adjusted gross margin improvement to approximately 52% [8]. - **CDMO**: Anticipated to achieve EBITDA breakeven by 2027, with a projected revenue increase of 20-25% [8]. - **Synthetic Biology**: Expected revenue growth of 10-15% with an adjusted gross margin improvement to around 43% [8]. Valuation and Earnings Forecast - The company is projected to generate revenues of USD 788 million and USD 910 million for 2026 and 2027, respectively, with a forecasted net profit of USD 22 million in 2026 and USD 343 million in 2027 [10][12]. - The estimated fair value of the company is HKD 35.543 billion, with a target price of HKD 16.26, reflecting a 20% discount based on comparable company valuations [10][14].

Core Insights - The management of Legend Biotech emphasized the increasing utilization of CARVYKTI earlier in treatment courses, with approximately 65% of patients now treated in the second- to fourth-line settings [1][5] - CARVYKTI net trade sales reached approximately $555 million in Q4 2025, marking a 66% year-over-year increase, supported by share gains and site expansion [3][6] - The company achieved profitability for CARVYKTI in 2025 and anticipates enterprise-wide profitability in 2026 [4][21] Sales Performance - In the U.S., net trade sales were reported at $420 million, a 38% increase year-over-year and a 6% sequential rise, attributed to shipment seasonality [2] - Outside the U.S., sales reached $135 million, more than tripling compared to the prior year and increasing by 5% sequentially, with notable strength in Germany, Spain, and Belgium [2] Clinical Data and Treatment Efficacy - Clinical data indicated a median progression-free survival of 50.4 months for triple-class-exposed patients, with 65% of patients treated in the second- to fourth-line settings [5][7] - Long-term data presented at key meetings showed that 80% of standard-risk patients remained progression-free after 2.5 years, with 93% of those progression-free at one year remaining alive and progression-free at 2.5 years [8] Manufacturing and Capacity - Legend Biotech has established manufacturing capacity for 10,000 doses, with plans to expand to 20,000 doses in collaboration with Johnson & Johnson, achieving a manufacturing success rate of 97-99% [5][12][13] - The company reported improved gross margins, with a gross margin of 61% and a gross margin on CARVYKTI net product sales of 57% [15][14] Financial Results - The fourth-quarter revenue was reported at $306 million, a 64% increase year-over-year, with operating margin improving from -142% to -6% over ten consecutive quarters [15][17] - Legend Biotech ended the year with $949 million in cash and equivalents, with operating cash flow outlays significantly reduced from $82 million to $12 million year-over-year [18] Future Outlook - The company is committed to sequential growth throughout 2026, with management expressing confidence in achieving approximately 50% top-line growth year-over-year based on market consensus [19] - Investment priorities include advancing in vivo programs, supporting CARVYKTI profit expansion, and modest capital expenditures related to manufacturing [21]

Financial Data and Key Metrics Changes - In Q4 2025, revenue reached $306 million, reflecting a 64% year-over-year growth, with a gross margin of 61% [24][26] - The operating margin improved from -142% in Q2 2023 to -6% in Q4 2025, indicating significant operational leverage [24][26] - Adjusted net income was reported at $2.5 million, a transformation from a $59 million adjusted net loss a year ago [26] Business Line Data and Key Metrics Changes - CARVYKTI net trade sales were approximately $555 million in Q4 2025, a 66% increase year-over-year and a 6% increase from Q3 2025 [7][16] - U.S. net trade sales of CARVYKTI were $420 million, growing 38% year-over-year [16] - Outside the U.S., sales reached $135 million, representing over a threefold increase compared to the same period a year ago [16] Market Data and Key Metrics Changes - CARVYKTI is now offered in 14 global markets, with 294 treatment sites worldwide [16][18] - The majority of CARVYKTI utilization is in earlier line settings, with approximately 65% of patients treated in the second to fourth line settings [16][22] - The market for BCMA-directed therapies remains under-penetrated, with less than 5% of patients in the second through fourth line treated with a BCMA targeting agent in 2025 [17] Company Strategy and Development Direction - The company aims to achieve company-wide profitability in 2026, following CARVYKTI's profitability in 2025 [7][15] - There is a strategic focus on expanding CARVYKTI's use in earlier treatment lines, supported by clinical evidence showing better outcomes [17][23] - The partnership with Johnson & Johnson is aimed at scaling CARVYKTI to an anticipated peak annual sales potential of over $5 billion [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sequential growth throughout 2026, targeting approximately 50% top-line growth from the previous year [31] - The company is optimistic about the long-term growth potential of CARVYKTI, given the significant unmet needs in the multiple myeloma market [17][24] - Management highlighted the importance of effective bridging therapy in improving patient outcomes and safety [19][22] Other Important Information - The company ended the year with $949 million in cash equivalents, providing flexibility for future investments [27] - The Tech Lane facility in Belgium began commercial production in September 2025, supporting growth in ex-U.S. markets [16][17] - The company plans to file one to two U.S. INDs by the end of the year, focusing on advancing its R&D pipeline [14] Q&A Session Summary Question: Expectations for CARVYKTI growth in 2026 - Management expects sequential growth throughout 2026, confident in achieving approximately 50% top-line growth from last year [31] Question: Focused synergistic business development - The company is interested in complementary technologies and potential partnerships to accelerate the development of in vivo CAR T assets [32] Question: Positioning of bispecifics relative to CARVYKTI - Management believes there is a significant unmet need in second and third line settings, with a unique value proposition for CARVYKTI [35] Question: Community setting expansion hurdles - Continued education and training for community physicians are essential for expanding CARVYKTI's adoption in community hospitals [39] Question: Current CAR-T penetration targets - The company sees significant growth potential in both late-line and early-line multiple myeloma treatments, with a focus on improving patient outcomes [44][46] Question: Impact of recent M&A in the space - The acquisition of a competitor validates the market's value, with the company prepared for increased competition [58][59] Question: MRD results and potential filing acceleration - The company is exploring the correlation between MRD activity and clinical outcomes, which could accelerate FDA filing times for future trials [70]

Financial Data and Key Metrics Changes - In Q4 2025, revenue reached $306 million, representing a 64% year-over-year growth [23] - Gross margin remained strong at 61%, with CARVYKTI net product sales gross margin at 57% [23] - Operating margin improved from -142% in Q2 2023 to -6% in Q4 2025, reflecting operational leverage [23][24] - Adjusted net income was reported at $2.5 million, a significant improvement from a $59 million adjusted net loss a year ago [25] Business Line Data and Key Metrics Changes - CARVYKTI net trade sales were approximately $555 million in Q4 2025, a 66% increase year-over-year [7] - U.S. net trade sales of CARVYKTI were $420 million, growing 38% year-over-year [16] - Outside the U.S., sales reached $135 million, representing over a 3x increase compared to the same period a year ago [16] Market Data and Key Metrics Changes - CARVYKTI is now offered in 14 global markets, with 294 treatment sites worldwide [16] - The majority of CARVYKTI utilization is in earlier line settings, with approximately 65% of patients from the second to fourth line [16] - BCMA-directed therapies remain under-penetrated in earlier lines, with less than 5% of patients in the second through fourth line treated with a BCMA targeting agent in 2025 [17] Company Strategy and Development Direction - The company aims to become a fully scaled CAR-T leader and achieve company-wide profitability in 2026 [7] - There is a strategic focus on expanding CARVYKTI's use in earlier lines, supported by evidence showing better outcomes with earlier intervention [17][22] - The partnership with Johnson & Johnson is aimed at scaling CARVYKTI to an anticipated potential of over $5 billion in peak annual sales [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sequential growth throughout 2026, targeting approximately 50% top-line growth from the previous year [31] - The company is optimistic about the long-term growth potential of CARVYKTI, given the significant unmet needs in the multiple myeloma market [17][22] - Management highlighted the importance of effective bridging therapy in improving patient outcomes and safety [19][88] Other Important Information - The company ended the year with $949 million in cash equivalents, providing flexibility for future investments [26] - The company plans to file one to two U.S. INDs by the end of the year, focusing on advancing its R&D pipeline [14] Q&A Session Summary Question: Expectations for CARVYKTI growth in 2026 and business development focus - Management expects sequential growth throughout 2026, confident in delivering approximately 50% top-line growth [31] - Business development efforts will focus on complementary technologies and potential partnerships to accelerate global development [32] Question: Positioning of bispecifics in early lines relative to CARVYKTI - Management believes there is a significant unmet need in second and third lines, with a unique value proposition for CARVYKTI as a one-time infusion [35] Question: Hurdles for community setting expansion - Continued education and training for community physicians are crucial for expanding CARVYKTI's adoption in community hospitals [40] Question: Current CAR-T penetration and growth opportunities - Management sees significant growth opportunities across all segments, including academic centers and community hospitals, with a focus on early line use [48] Question: Impact of recent M&A in the space - The acquisition of a competitor validates the market's value, with management confident in CARVYKTI's unmatched efficacy and durability [60] Question: Pipeline strategy and long-term data confidence - Management is particularly excited about in vivo CAR-T approaches, leveraging their experience with lentiviral vectors while remaining open to exploring other technologies [82]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 reached $306 million, representing a 64% year-over-year growth [22] - Gross margin remained strong at 61%, with CARVYKTI net product sales gross margin at 57% [22] - Operating margin improved from -142% in Q2 2023 to -6% in Q4 2025, reflecting operational leverage [22][24] - Adjusted net income was reported at $2.5 million, a significant improvement from a $59 million adjusted net loss a year ago [24] Business Line Data and Key Metrics Changes - CARVYKTI net trade sales were approximately $555 million in Q4 2025, a 66% increase year-over-year [5][14] - U.S. net trade sales of CARVYKTI were $420 million, growing 38% year-over-year [14] - Outside the U.S., sales reached $135 million, representing over a threefold increase compared to the same period last year [14] Market Data and Key Metrics Changes - CARVYKTI is now offered in 14 global markets, with 294 treatment sites worldwide [14] - The majority of CARVYKTI patients (approximately 65%) are from the second to fourth line settings [14][76] - BCMA-directed therapies remain under-penetrated in earlier lines, with less than 5% of patients in the second through fourth line treated with a BCMA targeting agent in 2025 [15] Company Strategy and Development Direction - The company aims to achieve company-wide profitability in 2026, following CARVYKTI's profitability in 2025 [5][13] - Focus on expanding CARVYKTI's use in earlier treatment lines, supported by clinical evidence showing better outcomes [15][20] - Plans to file one to two U.S. INDs by the end of the year and to explore synergistic business development opportunities [12][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sequential growth throughout 2026, targeting approximately 50% top-line growth for CARVYKTI [30] - The company is optimistic about capturing a significant market share in the under-penetrated multiple myeloma market [15][45] - Management highlighted the importance of effective bridging therapy in improving patient outcomes and safety [19][90] Other Important Information - The company ended the year with $949 million in cash equivalents, providing flexibility for future investments [25] - Manufacturing capacity has been expanded to support annual production of 10,000 doses, with plans to increase to 20,000 doses [11][52] Q&A Session Summary Question: Expectations for CARVYKTI growth in 2026 and business development focus - Management expects sequential growth throughout 2026, confident in achieving approximately 50% top-line growth [30] - Business development efforts will focus on complementary technologies and potential partnerships to accelerate global development [31] Question: Positioning of bispecifics in early lines relative to CARVYKTI - Management noted a significant unmet need in second and third lines, with CARVYKTI's unique value proposition supporting its growth in these settings [34] Question: Community setting expansion hurdles - Continued education and training for community physicians are essential for expanding CARVYKTI's adoption in community hospitals [39][40] Question: Current CAR-T penetration targets - Management believes there is significant growth potential in both late and early lines, with plans to increase annual supply to meet demand [45][47] Question: Competitive dynamics following recent M&A in the space - The acquisition of a competitor validates the market's value, with management confident in CARVYKTI's unmatched efficacy and durability [59][61] Question: Pipeline strategy and in vivo programs - The company is particularly excited about in vivo CAR T approaches due to their convenience and potential for broader applications [82]

Core Insights - Legend Biotech Corporation reported strong financial results for Q4 and the full year 2025, highlighting significant growth in collaboration revenue and advancements in its CAR-T therapy, CARVYKTI [1][5][7]. Financial Performance - As of December 31, 2025, Legend Biotech had approximately $949 million in cash and cash equivalents and time deposits [4][7]. - Collaboration revenue for Q4 2025 was $277.6 million, a 65.2% increase from $168.0 million in Q4 2024, driven by CARVYKTI sales under the Janssen collaboration [5]. - License and other revenue rose to $28.7 million in Q4 2025 from $18.5 million in Q4 2024, primarily due to a milestone achievement under the Janssen Agreement [6]. - Total revenue for the year ended December 31, 2025, was $1.0289 billion, compared to $627.3 million in 2024 [20]. - The operating loss for Q4 2025 was $19.7 million, significantly improved from a loss of $79.3 million in Q4 2024 [13]. - Net loss for Q4 2025 was $30.9 million, or $0.08 per share, compared to a net income of $26.4 million, or $0.07 per share, in Q4 2024 [14]. Business Developments - CARVYKTI has treated over 10,000 patients and achieved franchise profitability for the full year 2025 [2][7]. - The company expanded its manufacturing capabilities, completing an expansion at its Raritan facility, which is now the largest cell therapy manufacturing site in the U.S. [7]. - CARVYKTI is now available in 14 markets across 294 sites worldwide, with ongoing efforts to increase adoption in community settings [7]. - The company advanced its early-stage cell therapy portfolio, including the first patient dosing of in vivo candidates and presented first-in-human results for LUCAR-G39D, an allogeneic CAR-T therapy [6][7]. Research and Development - Research and development expenses for Q4 2025 were $101.3 million, a slight decrease from $104.4 million in Q4 2024, reflecting lower expenditures in BCMA clinical programs [10]. - The company opened a new 31,000-square-foot R&D facility in Philadelphia, Pennsylvania, to support its development efforts [7]. Market Position - Legend Biotech is positioned as a leader in cell therapy, particularly with its CARVYKTI product, which is pivotal in the treatment of relapsed or refractory multiple myeloma [17].

Company Overview - Legend Biotech (LEGN) is rated as a "Buy" with a target price of $46.41, representing a potential upside of 138% from the current price of $19.5[5] - The company is expected to achieve profitability in 2026, driven by the sales growth of its product CARVYKTI[5] Financial Performance - CARVYKTI generated $1.887 billion in revenue for 2025, with a year-on-year growth of 95.9%[10] - The company forecasts total revenue of $1.412 billion for 2026, reflecting a growth rate of 39.7%[9] - Legend Biotech's earnings per share (EPS) is projected to turn positive at $0.28 in 2026, after losses in previous years[9] Production Capacity - The company has four global production facilities, with an expected annual capacity of 10,000 doses upon FDA approval in Q1 2026[5] - A $200 million investment is planned to expand the production capacity in Ghent, Belgium, aiming for 20,000 doses by 2028[5] Competitive Landscape - Legend Biotech's CART-4 trial includes a higher percentage of more severe patients compared to Johnson & Johnson's MajesTEC-3 trial, indicating a competitive edge in clinical data[6] Valuation Metrics - A discounted cash flow (DCF) analysis assumes a weighted average cost of capital (WACC) of 10% and a perpetual growth rate of 0%, leading to a target price of $46.41[8]

Company Overview - Legend Biotech Corporation is a global leader in cell therapy with over 2,900 employees, making it the largest standalone cell therapy company [3] - The company is pioneering treatments that significantly change cancer care, particularly through its CAR-T cell therapy, CARVYKTI, which is a one-time treatment for relapsed or refractory multiple myeloma [3] - Legend Biotech collaborates with Johnson & Johnson for the development and marketing of CARVYKTI and aims to maximize patient access and therapeutic potential [3] Upcoming Financial Event - Legend Biotech will host a conference call for investors on March 10, 2026, at 8:00 am ET to review the fourth-quarter and full-year 2025 financial results [1] - Senior management will provide an overview of the company's quarterly and full-year financial performance during the call [1] Investor Relations - Investors can access the live audio webcast of the conference call via a provided weblink, and a replay will be available in the Investor Relations section of the Legend Biotech website approximately two hours after the call [2]

Group 1 - The core viewpoint of the report indicates that autologous CAR-T therapies face challenges due to complex preparation processes and high costs, especially with the emergence of TCE therapies showing comparable efficacy [1] - The global sales of autologous CAR-T therapies are projected to reach approximately $5.9 billion by 2025, reflecting a year-on-year growth of 30% [1] - The ASH 2025 conference revealed data from the MajesTEC-3 study, demonstrating that BCMATCE combined with daratumumab shows efficacy comparable to CARVYKTI, with better progression-free survival (PFS) rates, highlighting the need for breakthroughs in autologous CAR-T therapies [1] Group 2 - In vivo CAR-T therapies, which are simpler to produce and less costly, are seen as having significant potential, with over 20 clinical-stage in vivo CAR-T pipelines currently in early development [2] - Five in vivo CAR-T products have reported human data, showing short-term efficacy comparable to autologous CAR-T, with some products exhibiting superior safety profiles [2] - LNP vector products require multiple doses but have shown excellent safety, with preliminary efficacy signals observed in autoimmune diseases, indicating potential future success in this area [2] Group 3 - Since 2025, over 10 transactions related to in vivo CAR-T have occurred, with major pharmaceutical companies like AstraZeneca, AbbVie, and BMS actively investing in this space [3] - The report anticipates the release of over ten new clinical data readouts this year, many of which will be first-time results from pipelines that previously disclosed early data [3] - The clinical performance of in vivo CAR-T has been preliminarily validated, with increasing certainty in the technology's pathway, suggesting it may become the mainstream form of CAR-T therapy in the future [3]

Group 1: Performance Outlook - The company projects its 2026 operational sales to be between $99.5 billion and $100.5 billion, with adjusted earnings per share expected to range from $11.43 to $11.63, exceeding Wall Street analysts' expectations [1] - Growth is primarily driven by innovative drugs such as TREMFYA, DARZALEX, and CARVYKTI, along with new medical technology products [1] Group 2: Recent Events - A significant trial regarding the association of Johnson & Johnson's talc products with ovarian cancer is expected to commence in the second half of 2026, involving substantial claims; however, the company asserts product safety and plans to respond proactively [2] - The company intends to separate its slower-growing orthopedic business from its overall operations within 18 to 24 months from the end of 2025, focusing on high-growth areas as part of its transformation strategy [2] - As one of the 16 pharmaceutical companies that reached a drug price reduction agreement with the Trump administration, the company will face a financial impact of "hundreds of millions" due to drug price cuts, but management has incorporated this into the 2026 performance outlook while maintaining growth resilience [2]